JP2006522128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006522128A5 JP2006522128A5 JP2006509461A JP2006509461A JP2006522128A5 JP 2006522128 A5 JP2006522128 A5 JP 2006522128A5 JP 2006509461 A JP2006509461 A JP 2006509461A JP 2006509461 A JP2006509461 A JP 2006509461A JP 2006522128 A5 JP2006522128 A5 JP 2006522128A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- optionally
- aryl
- conr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 126
- 125000003118 aryl group Chemical group 0.000 claims 32
- 150000002367 halogens Chemical class 0.000 claims 29
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- HCUOEKSZWPGJIM-IYNMRSRQSA-N (e,2z)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N\O)\C(N)=O HCUOEKSZWPGJIM-IYNMRSRQSA-N 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000002877 alkyl aryl group Chemical group 0.000 claims 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 6
- -1 —C 3-7 cycloalkyl Chemical group 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 208000027753 pain disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- UDRTVTUKDKTWBS-UHFFFAOYSA-N 1-[3-(1-pyridin-2-ylimidazol-4-yl)phenyl]pyrrolo[2,3-c]pyridine Chemical compound C1=CC2=CC=NC=C2N1C(C=1)=CC=CC=1C(N=C1)=CN1C1=CC=CC=N1 UDRTVTUKDKTWBS-UHFFFAOYSA-N 0.000 claims 1
- XOHFUICATLXZFV-UHFFFAOYSA-N 2-[1-(3-methyl-5-pyridin-3-ylphenyl)imidazol-4-yl]pyridine Chemical compound C=1C(C)=CC(C=2C=NC=CC=2)=CC=1N(C=1)C=NC=1C1=CC=CC=N1 XOHFUICATLXZFV-UHFFFAOYSA-N 0.000 claims 1
- RQUDXRSCJBXBOK-UHFFFAOYSA-N 2-[2-fluoro-4-(4-pyridin-2-ylimidazol-1-yl)phenyl]pyridine Chemical compound FC1=CC(N2C=C(N=C2)C=2N=CC=CC=2)=CC=C1C1=CC=CC=N1 RQUDXRSCJBXBOK-UHFFFAOYSA-N 0.000 claims 1
- CIUKMNNQDQZPQK-UHFFFAOYSA-N 2-[3-methyl-5-(4-pyridin-2-ylimidazol-1-yl)phenyl]benzonitrile Chemical compound C=1C(C)=CC(C=2C(=CC=CC=2)C#N)=CC=1N(C=1)C=NC=1C1=CC=CC=N1 CIUKMNNQDQZPQK-UHFFFAOYSA-N 0.000 claims 1
- KFHUDVLJSWLWNL-UHFFFAOYSA-N 2-[4-(3-pyridin-3-ylphenyl)imidazol-1-yl]pyridine Chemical compound C1=NC(C=2C=C(C=CC=2)C=2C=NC=CC=2)=CN1C1=CC=CC=N1 KFHUDVLJSWLWNL-UHFFFAOYSA-N 0.000 claims 1
- DSZSHLFRXIEFAX-UHFFFAOYSA-N 2-[4-(4-pyridin-3-ylphenyl)imidazol-1-yl]pyridine Chemical compound C1=NC(C=2C=CC(=CC=2)C=2C=NC=CC=2)=CN1C1=CC=CC=N1 DSZSHLFRXIEFAX-UHFFFAOYSA-N 0.000 claims 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 229940089973 Sodium channel antagonist Drugs 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical class 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 239000000472 muscarinic agonist Substances 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- 239000003402 opiate agonist Substances 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 230000000697 serotonin reuptake Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46002903P | 2003-04-03 | 2003-04-03 | |
| PCT/US2004/009658 WO2004087653A2 (en) | 2003-04-03 | 2004-03-30 | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522128A JP2006522128A (ja) | 2006-09-28 |
| JP2006522128A5 true JP2006522128A5 (enExample) | 2007-04-26 |
Family
ID=33131911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509461A Withdrawn JP2006522128A (ja) | 2003-04-03 | 2004-03-30 | 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060217420A1 (enExample) |
| EP (1) | EP1613615A2 (enExample) |
| JP (1) | JP2006522128A (enExample) |
| CN (1) | CN100422175C (enExample) |
| AU (1) | AU2004225887A1 (enExample) |
| CA (1) | CA2520863A1 (enExample) |
| WO (1) | WO2004087653A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| EP1482931B1 (en) | 2002-03-05 | 2011-10-19 | TransTech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| EP1613614A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| CN1845915A (zh) * | 2003-09-02 | 2006-10-11 | 默克公司 | 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物 |
| EP1715867A4 (en) * | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
| WO2006123255A2 (en) * | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| US7858649B2 (en) * | 2005-10-14 | 2010-12-28 | Neurosearch A/S | Imidazole derivatives and their use for modulating the GABAA receptor complex |
| WO2007113202A1 (en) | 2006-03-31 | 2007-10-11 | Glaxo Group Limited | Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| WO2009097414A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Use of imidazolylalkyl-pyridines for the treatment of addictive disorders |
| CA2772797C (en) | 2009-09-30 | 2018-09-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives |
| KR20150064743A (ko) | 2012-10-05 | 2015-06-11 | 트랜스테크 파르마 엘엘씨 | 경도 및 중등도 알츠하이머 병의 치료 |
| US9969726B2 (en) * | 2014-06-10 | 2018-05-15 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物 |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US660753A (en) * | 1899-11-27 | 1900-10-30 | Ferdinand-Christoph Von Heydebrand Und Der Lasa | Artificial fuel. |
| US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| GB9713726D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CA2462289C (en) * | 2001-10-04 | 2010-02-23 | Nicholas D. Cosford | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| AU2002365892A1 (en) * | 2001-11-30 | 2003-06-17 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
| EP1458708B1 (en) * | 2001-12-18 | 2007-09-26 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| JP4357965B2 (ja) * | 2001-12-21 | 2009-11-04 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピロールモジュレーター |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| EP1613614A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| CN100537564C (zh) * | 2003-04-04 | 2009-09-09 | 麦克公司 | 代谢型谷氨酸受体-5的二芳基取代三唑调节剂 |
| EP1613265A4 (en) * | 2003-04-04 | 2007-02-14 | Merck & Co Inc | DI-ARYL-SUBSTITUTED PYRROL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
| CN1845915A (zh) * | 2003-09-02 | 2006-10-11 | 默克公司 | 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物 |
| US20060189661A1 (en) * | 2003-11-03 | 2006-08-24 | Wagenen Bradford V | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1715867A4 (en) * | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
-
2004
- 2004-03-30 JP JP2006509461A patent/JP2006522128A/ja not_active Withdrawn
- 2004-03-30 AU AU2004225887A patent/AU2004225887A1/en not_active Abandoned
- 2004-03-30 WO PCT/US2004/009658 patent/WO2004087653A2/en not_active Ceased
- 2004-03-30 CN CNB200480008683XA patent/CN100422175C/zh not_active Expired - Fee Related
- 2004-03-30 CA CA002520863A patent/CA2520863A1/en not_active Abandoned
- 2004-03-30 EP EP04749518A patent/EP1613615A2/en not_active Withdrawn
- 2004-03-30 US US10/552,107 patent/US20060217420A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509150A5 (enExample) | ||
| CA2478799A1 (en) | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| WO2009082268A3 (ru) | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| JP2011504490A5 (enExample) | ||
| EA200970369A1 (ru) | Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака | |
| MX2010005342A (es) | Compuestos indola y metodos para tratar el dolor visceral. | |
| JP2010523556A5 (enExample) | ||
| FI3856182T3 (fi) | Koostumuksia ja menetelmiä muskariinireseptorin aktivaation lievittämien häiriöiden hoitamiseksi | |
| JP2007519649A5 (enExample) | ||
| JP2005504126A5 (enExample) | ||
| JP2008501000A5 (enExample) | ||
| JP2011500638A5 (enExample) | ||
| HRP20161116T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3 | |
| JP2010155827A5 (enExample) | ||
| JP2012512158A5 (enExample) | ||
| JP2019526571A5 (enExample) | ||
| CN105085482B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| JP2008539268A5 (enExample) | ||
| JP2011500621A5 (enExample) | ||
| CN100422175C (zh) | 作为代谢型谷氨酸受体-5调制剂的四环咪唑衍生物 | |
| JP2005536507A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| JP2010531292A5 (ja) | １１−ピペラジン−１−イルジベンゾ[ｂ,ｆ][１,４]チアゼピンの誘導体及びその使用 | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten |